Key Drivers
- Strong Liquidity
- Thin Margins
- Weak Returns
AIAI Summary
PCRX is shifting toward a cash-generative commercial pain franchise, with expanded outpatient EXPAREL reimbursement offering the clearest catalyst for growth acceleration, but investors should wait for sustained uptake, stronger margin/interest coverage, and durable free-cash-flow conversion before underwriting a rerating; PCRX-201 remains upside optionality rather than a base-case driver until efficacy data validate it.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Thin Margins
- •Weak Returns
PCRX has strong liquidity and cash flow, but thin profitability, weak returns, moderate leverage, and a demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
PCRX remains mildly positive over the last month but is weakening below its moving average, with $24.00 support critical and $25.40 resistance needing a reclaim.
Declined from the $26.60 peak to $24.08 before a modest rebound
Sentiment & News
Key News Insights:
- •New Hire Grants
- •Nasdaq Compliance
- •No Business Update
Pacira issued employment inducement equity grants to five new hires, with no operational or financial update.
The announcement is neutral for Pacira, reflecting routine hiring-related compensation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings